Skip to search formSkip to main contentSkip to account menu

RO 5072759

Known as: RO-5072759, RO5072759 
National Institutes of Health

Related topics

Related topics

2 relations
GA 101

Broader (1)

obinutuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is… 
Review
2011
Review
2011
New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits… 
2010
2010
Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)
Abstract 1833 Background and Objective: GA101 is the first type II glycoengineered and humanized monoclonal anti-CD20 antibody to… 
2009
2009
Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).
Abstract 1704 Poster Board I-730 Background RO5072759 (GA101) is the first humanized and glycoengineered type II monoclonal anti… 
Review
2009
Review
2009
A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease.
Abstract 934 Background: GA101 (RO5072759) is the first humanized glycoengineered type II anti-CD20 monoclonal antibody to enter… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)